News About: Pharm. Industry
Multinational companies active in conducting domestic clinical trials
It was observed multinational companies have actively conducted domestic clinical trials to develop new drugs.
According to the clinical trial approval report of the Ministry of Food and Drug Safety, 6 multinational ...
Celltrion Healthcare receives Tower of $300 Million Exports for the first time as a pharmaceutical companyCelltrion Healthcare was awarded the ‘Tower of $300 Million Exports(1 July 2014 to 30 June 2015)’ at the 2015 52nd Trade Day ceremony hosted by the Korea International Trade Ass...
|
Chong Kun Dang exclusively sells female sexual dysfunction treatment for the first time in KoreaChong Kun Dang(CEO Young-joo Kim) established an exclusive sales agreement of a female sexual dysfunction treatment with S1 Biopharma, a U.S. company, at the Chong Kun Dang head...
|
Samsung Bioepis hurries to launch pharmaceutical products, acquiring the second product approval
Samsung Bioepis announced acquisition of product approval of Renflexis(Remicade biosimilar), an autoimmune disease treatment, from the Ministry of Food and Drug Safety on the 4th.
Thus, Samsung Bioepis has become a c...
MSD Korea launches Brenzys™ in Korea for the first timeOn the 3rd, MSD Korea(CEO Dong-wook Hyun) announced Samsung Bioepis will launch Brenzys™, a biosimilar the company developed and commercializes, for the first time in the world....
|
Amgen Korea announces approval of Blincyto as acute lymphoblastic leukemia treatmentAmgen Korea announced commercialization approval of Blincyto Inj 35μg(generic name: blinatumomab), an acute lymphoblastic leukemia (ALL: Acute Lymphoblastic Leukemia) treatment,...
|
Market capitalization of biopharmaceutical companies exceeds KRW 1 trillion
It was observed the average R&D investment ratio of listed biopharmaceutical companies to sales exceeded 20%.
The phenomenon seems biopharmaceutical ventures have to spend an enormous amount of R&D expenses, but have...
Total reserves of listed pharmaceuticals reach KRW 11.5 trillion
It was analyzed the total reserves owned by listed pharmaceutical companies reach KRW 11.5 trillion and Yuhan Corporation become the highest surplus owning company with KRW 1.2621 trillion in the pharmaceutical indust...
‘Brensis’ attracted interests among other highlighted domestic biosimilars
‘Brensis,’ a biosimilar of MSD and Samsung Bioepis, and its follow-up biosimilars have attracted interests. Since domestic biosimilars have competitiveness in quality and price in the global market of biomedicines whi...
Pharmaceutical wholesalers glad to see Pfizer Korea’s distribution cost raisesAs Pfizer Korea increased distribution cost as Novartis Korea did so, pharmaceutical distribution companies have been delighted to them.
According to the industry concerned on ...
|
